Rhodiola Rosea: Nootropic Benefits, Uses, Dosage, & Side Effects

Rhodiola Rosea is an adaptogen, a herb claimed to raise resistance to stress. Its root extract at 576 mg per day for 28 days reduced fatigue on Pines’ burnout scale (a symptom rating scale) and attention errors more than placebo in 60 adults with stress-related fatigue, 30 per group.⁽¹⁾ It is used mainly for stress-related mental fatigue.

In placebo-controlled human trials, Rhodiola Rosea lowered mental fatigue under stress; memory effects come from animal studies, and neither Rhodiola Rosea nor sertraline differed significantly from placebo in the one depression trial that compared them.

Side effects are few: the EU herbal monograph lists headache and nausea with unknown frequency,⁽²⁾ and the 12-week depression trial recorded dizziness and nervousness in a few Rhodiola Rosea users (counts under Rhodiola Rosea Side Effects & Safety).⁽³⁾

What is Rhodiola Rosea?

Rhodiola Rosea (also known as Rosenroot, Rhodiola Rhizome, Golden Root, and Arctic Root), is a medicinal herb in the Rhodiola genus. It is native to the cold, arctic regions of Europe and Asia, and is used as an anti-fatigue nootropic (one of the natural nootropics) and adaptogen. Variant spellings of the name include rhodeola rosea, rodeo rosaya, rodeo la rosa, roseo herb, rholodio, rodeora rosas, rhodeo rosala, rosa rhoia and rodeo rose.

Rhodiola Rosea is a different plant from other Rhodiola species, such as Rhodiola crenulata, and from similar-sounding herbs like Rosa damascena. Rhodiola crenulata, a Chinese species, was found to contain no rosavin, the marker compound of Rhodiola Rosea; in a 2015 analysis of commercial samples, about 30% of crude root specimens sold as Rhodiola rosea were judged adulterated with crenulata because they contained no rosavin.⁽⁴⁾

Rhodiola Rosea at a glance:

• Plant part used: rhizome and root (Rhodiolae roseae rhizoma et radix)
• Marker compounds: rosavins (rosavin, rosarin, rosin) and salidroside (also listed as rhodioloside); rosavin distinguishes Rhodiola Rosea from related Rhodiola species
• Chemical identity: salidroside is C14H20O7 with a molecular weight of 300.30 (PubChem CID 159278)⁽⁵⁾ and rosavin is C20H28O10 with a molecular weight of 428.4 (PubChem CID 9823887)⁽⁶⁾
• Usual standardization: 3% rosavins and 1% salidroside
• EU regulatory status: traditional herbal medicinal product for the relief of symptoms of stress, such as fatigue and exhaustion, based on long-standing use; dry extract 1.5-5:1 made with 67-70% ethanol⁽²⁾
• Human trial doses: 100 mg per day to 680 mg per day, single doses of 200 to 555 mg, and 1,360 mg per day by escalation in one 12-week trial; the EU label dose is 144 to 400 mg per day
• Half-life in humans: about 2.5 hours for salidroside and 1.4 hours for rosavin after one oral 288 mg dose, in one 16-person study
• Main targets: MAO-A and MAO-B (in vitro), hippocampal serotonin (in rats); the stress-hormone (cortisol) response is covered under Rhodiola Rosea and Cortisol

Pros:

• Lowered mental fatigue and shortened reaction time in small placebo-controlled trials
• Small endurance gain after a single dose in two crossover trials
• Lowered self-rated anxiety and stress in one randomized trial that had a no-treatment control and no placebo
• Numerically fewer people reported adverse events than on sertraline in one 12-week depression trial (the pairwise difference was not statistically significant)

Cons:

• Four weeks of daily use did not improve endurance, and the benefits shown are small
• Trials are small (12 to 161 participants) and last up to 12 weeks; long-term efficacy and safety are not established
• Product quality varies: in one analysis of about 40 products sold as Rhodiola Rosea, about one in five contained no rosavin
• Lowered the activity of the liver enzyme CYP2C9 in a 14-day study of 13 volunteers, which may matter for warfarin and phenytoin users

Mechanism of Action

The mechanism of action of Rhodiola Rosea is still under investigation. The findings so far:

1. Stress Response: the hypothalamic-pituitary-adrenal (HPA) axis is the body’s stress-hormone chain; the human cortisol results are under Rhodiola Rosea and Cortisol.
2. Neurotransmitter Interaction: Rhodiola Rosea may act on mood and stress through monoamine neurotransmitters such as serotonin, dopamine, and norepinephrine; this is inferred from lab data. In vitro, methanol and water extracts of the root inhibited the monoamine-degrading enzyme MAO-A by 92.5% and 84.3% and MAO-B by 81.8% and 88.9% at 100 micrograms per millilitre.⁽⁷⁾
3. Antioxidant status and neuroprotection: the human evidence is a rise in plasma antioxidant capacity (see Neuroprotection); protection of brain cells is not shown in humans.
4. Synaptic activity: rosavin, salidroside and commercial extracts strengthened synaptic responses in rat hippocampus slices (see Rosavin).
5. Anti-Fatigue Effects: mental fatigue fell in human trials (see Nootropic Benefits); the mechanism is not established, and the monoamine and cortisol findings are candidates.

If Rhodiola Rosea constituents reach the brain at enough concentration to inhibit MAO-A and MAO-B, monoamine levels would rise, which would fit the mood and anti-fatigue results; this link is inferred, not measured in people.

Salidroside, one of the two marker compounds, had a plasma half-life of about 1 hour after intravenous dosing in rats, and the brain held the lowest salidroside concentration of the tissues measured.⁽⁸⁾ In 16 healthy volunteers given one 288 mg dose of Rhodiola Rosea extract, salidroside and rosavin peaked after 2 hours, and levels fell below detection by 8 hours,⁽⁹⁾ with elimination half-lives of about 2.5 hours for salidroside and 1.4 hours for rosavin,⁽¹⁰⁾ so levels fall within hours of a dose, which fits trials that split the daily dose (inferred).

Rhodiola Rosea and Cortisol

Rhodiola Rosea lowered the cortisol response to awakening in adults with stress-related fatigue but did not change cortisol in healthy, active men. In the 28-day fatigue trial, the cortisol response to awakening differed significantly between the Rhodiola Rosea and placebo groups from before to after treatment, and the authors report that Rhodiola Rosea decreased it.⁽¹⁾ In 26 healthy male students given 600 mg per day for 4 weeks, cortisol, testosterone and growth hormone did not change,⁽¹¹⁾ and in an acute cycling trial with 3 mg/kg salivary cortisol showed no significant difference from placebo.⁽¹²⁾

Rhodiola Rosea therefore does not raise cortisol in the trials that measured it; a lower morning cortisol surge would, if it holds in larger trials, fit the burnout-scale improvement in fatigued adults.

Rosavin: Key Active Compound in Rhodiola Rosea

Rosavin is a marker compound of Rhodiola Rosea: it is the compound used to distinguish Rhodiola Rosea from related species, which makes it the label check for genuine products.⁽¹³⁾ The human trials in the evidence table tested whole extracts, so none of their results is specific to rosavin.

Laboratory finding for rosavin:

• Synaptic Activity: In hippocampus slices from rats, rosavin, salidroside and every commercial Rhodiola Rosea extract tested strengthened the response of pyramidal cells to electrical stimulation, a lab model of memory formation (in vitro).⁽¹⁴⁾

Rhodiola Rosea supplements are usually standardized to 3% rosavins and 1% salidroside, yet measured content differs widely: across seven commercial extracts, rosavin ranged from none (one extract from China lacked it) to 3.7%; the lowest of the six extracts that contained rosavin held 0.03%.⁽¹⁴⁾

A 3% rosavins label means each 100 mg of extract carries about 3 mg of rosavins; a 200 mg capsule standardized this way supplies about 6 mg of rosavins and 2 mg of salidroside, and the 340 mg capsules used in a US depression trial carried 3.07% rosavin and 1.95% salidroside (listed as rhodioloside), about 10.4 mg and 6.6 mg.

Soluma, a Rhodiola Rosea supplement, lists 400 mg of Rhodiola Rosea extract standardized to 3% rosavins and 1% salidroside on its ingredients page, which works out to about 12 mg of rosavins and 4 mg of salidroside.⁽¹⁵⁾

Nootropic Benefits of Rhodiola Rosea

Rhodiola Rosea benefits in human trials centre on mental fatigue, reaction time, stress ratings and short bouts of endurance exercise; memory benefits come from rat studies.

The human trials behind each benefit, with design, size, dose and result. RCT means randomized controlled trial, in which people are assigned to a treatment by chance. In a crossover trial every participant takes both treatments in turn, and open-label means participants knew they were taking Rhodiola Rosea:

Jowko 2018 enrolled only men, Olsson 2009 both sexes, and Mao 2015 men and women (26 of 57, or 45.6%, were female);⁽³⁾ none of these trials split results by sex, so whether benefits differ between men and women is not established.

1. Cognitive Enhancement

Rhodiola Rosea improves mental performance mainly under fatigue and stress. In 161 cadets aged 19 to 21 working against a background of fatigue, a single dose of 370 or 555 mg (2 or 3 capsules of 185 mg) raised the antifatigue index, a ratio score from mental-work tests on which higher means less fatigue, by 14.8% (2 capsules) and 12.7% (3 capsules) relative to placebo (p < 0.001), with no difference between the two doses.⁽¹⁶⁾

This nootropic effect extends to improving mental focus and concentration during night work: 56 young physicians on night duty scored better on tests of associative thinking, short-term memory, calculation, concentration and audio-visual perception during the first 2-week period on 170 mg once daily (one tablet).⁽¹⁷⁾

Rhodiola Rosea also shortened reaction time in rested, healthy people. In 26 healthy male students, 13 per group, 600 mg per day (200 mg three times daily) for 4 weeks shortened simple reaction time from 247.8 to 226.5 ms, a 21.3 ms improvement (the paper reports 9.5%, presumably an average of each person’s relative change; 21.3 of the 247.8 ms group mean is 8.6%), while the change in the placebo group was not significant; the relative change differed between groups (p < 0.05).⁽¹¹⁾ Faster reaction time would, if the effect holds in larger groups, help in tasks that reward quick responses, such as driving or competitive games.

2. Learning and Memory in Rats

Rhodiola Rosea improved memory and learning in rats, including rats whose memory was impaired with scopolamine.

In rats, a standardized commercial Rhodiola extract increased correct avoidance responses during learning and on memory retention tests, both in normal rats and in rats whose memory was impaired with scopolamine, a drug that blocks acetylcholine receptors.⁽¹⁸⁾ The 14-day anxiety trial in people found no cognitive difference, so a memory benefit in people is inferred from animal data, not established.

3. Neuroprotection (Not Shown in People)

Rhodiola Rosea has not been shown to protect neurons in people; the related findings are one blood marker and one lab result.

In healthy men, 600 mg per day (200 mg three times daily) for 4 weeks raised plasma total antioxidant capacity,⁽¹¹⁾ and in rat hippocampus slices rosavin and salidroside strengthened synaptic responses (see Rosavin). Protection against age-related cognitive decline would follow only if these findings translate into brain changes over years; no human trial tested that, so the benefit is inferred.

4. Reduces Stress and Anxiety

Rhodiola Rosea lowered self-rated anxiety and stress in mildly anxious adults. In 80 participants randomized to Rhodiola Rosea or no treatment, 200 mg taken before breakfast and 200 mg before lunch (400 mg per day) for 14 days reduced self-reported anxiety, stress, anger, confusion and depression compared with the no-treatment group, without changing cognitive test scores; the control group received no placebo.⁽¹⁹⁾

In adults with mild to moderate depression, Rhodiola Rosea at 340 mg per day (31 patients) or 680 mg per day (29 patients) for 6 weeks improved overall depression (measured with the Hamilton Depression Rating Scale, HAM-D, a clinician-rated depression questionnaire on which lower scores mean milder depression), insomnia, emotional instability and somatization scores, while the placebo group (29 patients) did not improve.⁽²⁰⁾ None of the human trials tested effects in ADHD. Other options for low mood are compared in nootropics for depression.

5. Serotonin and Sertraline

Rhodiola Rosea’s effects on serotonin, a neurotransmitter associated with mood regulation, are of particular interest because the root inhibits MAO-A, the enzyme that breaks serotonin down, in vitro.

Neither Rhodiola Rosea nor sertraline, a commonly prescribed selective serotonin reuptake inhibitor (SSRI) for depression and anxiety disorders, beat placebo in a 12-week US trial in 57 adults with mild to moderate major depressive disorder (20 on Rhodiola Rosea, 19 on sertraline, 18 on placebo): the trial reported no statistically significant difference in change over time in the HAM-D score among the three groups (p = 0.79 across all three groups, not a comparison of any single pair). The HAM-D score fell by 5.1 points on Rhodiola Rosea (95% CI -8.8 to -1.3), 8.2 on sertraline (-12.7 to -3.6) and 4.6 on placebo (-8.6 to -0.6). Every interval overlaps the placebo interval (a 95% CI, or confidence interval, is the range that likely contains the true value), so there is no clear difference from placebo. Doses started at one 340 mg capsule daily and were raised stepwise when HAM-D had fallen by 50% or less, up to four capsules (1,360 mg per day); the capsules carried 3.07% rosavin and 1.95% salidroside.⁽³⁾ Adverse-event rates are under Rhodiola Rosea Side Effects & Safety.

The trial did not combine Rhodiola Rosea with sertraline; the possible serotonin interaction with SSRIs is covered under Side Effects & Safety.

6. Neurogenesis in Rats

Rhodiola extract supported neurogenesis in stressed rats, restoring the growth of new cells in the hippocampus, the brain region that forms memories.

In 70 rats (10 per group) made depressed by chronic mild stress, 3 weeks of Rhodiola Rosea extract at 1.5, 3 or 6 g/kg (given by stomach tube) returned hippocampal serotonin to normal, and the lowest dose returned neural stem cell proliferation in the hippocampus to normal levels.⁽²¹⁾ The lowest rat dose, 1.5 g/kg, converts to a human equivalent of 1.5 x 6/37 = 0.24 g/kg, about 17 g for a 70 kg adult (body-surface-area conversion, Km rat 6, human 37; estimated equivalent, not a tested dose). That is at least about 12.5 times 1,360 mg per day (17.03 g / 1.36 g), the highest daily dose in the evidence table (Mao 2015); the paper does not state whether 1.5 g/kg was the daily total or each of two daily doses. A memory or mood benefit in people is inferred and untested.

7. Anti-Fatigue Effects

Rhodiola Rosea lowered mental fatigue in students under exam stress. Students who took two 50 mg tablets a day for 20 days during an examination period improved more than placebo in self-rated mental fatigue and a maze test of movement accuracy (p < 0.01), self-rated general well-being was also better (p < 0.05), and text-correction and tapping tests did not change.⁽²²⁾ Lower mental fatigue would serve students, shift workers and others whose work demands focus late in a long day.

8. Exercise Performance

Rhodiola Rosea taken 1 hour before exercise produced small endurance gains in two crossover trials. In 24 young adults, 200 mg of extract (3% rosavin, 1% salidroside) raised time to exhaustion from 16.8 to 17.2 minutes, 0.4 minutes or 2.4% (p < 0.05); in a 12-person follow-up, 4 weeks of 200 mg per day changed none of the measured variables, and the single-dose effect was still present after those 4 weeks.⁽²³⁾ In 18 adults, 3 mg/kg (210 mg at 70 kg) taken 1 hour before a 6-mile cycling time trial cut finish time from 25.8 to 25.4 minutes (0.4 minutes, 1.6% faster; p = 0.037) and perceived exertion from 6.6 to 6.0 on a 10-point scale (9.1% lower; p = 0.04).⁽¹²⁾

Daily use did not improve endurance: 600 mg per day for 4 weeks left endurance capacity unchanged in healthy male students, so Rhodiola Rosea would act on the perceived effort of a single session rather than on fitness built over weeks (inferred from the two trial patterns).

Uses of Rhodiola Rosea

Rhodiola Rosea is used mainly for stress-related mental fatigue, the best-supported human use. Measured outcome by use:

• Stress Reduction: Lowered self-rated stress and anxiety in one randomized trial without a placebo.
• Fatigue Alleviation: Reduced mental fatigue in placebo-controlled trials.
• Cognitive Enhancement: Improves focus and reaction time, mainly under fatigue.
• Mood Improvement: Lowered depression scores in one placebo-controlled trial but not in another.
• Exercise Performance: Small endurance gain after a single dose.
• Antioxidant Support: Raised plasma antioxidant capacity in healthy men.
• General Well-being: Students self-rated their general well-being better than placebo during exams.

Rhodiola Rosea is also combined with L-theanine, caffeine or ashwagandha in nootropic stacks (community practice, anecdotal, not studied).

Rhodiola Rosea Dosage

Label dose: the recommended dose of Rhodiola Rosea supplementation on EU traditional-use products (dry extract 1.5-5:1, 67-70% ethanol) is a single dose of 144 to 200 mg taken once or twice daily, 144 to 400 mg per day, for adults and the elderly; use under 18 years of age is not recommended, and a doctor should be consulted if symptoms persist longer than 2 weeks.⁽²⁾

Human trial doses: the evidence table under Nootropic Benefits gives the dose in mg and the frequency of each trial. Stated doses ran from 100 mg per day (Spasov 2000) to 680 mg per day (Darbinyan 2007), single doses from 200 to 555 mg, and 1,360 mg per day reached by dose escalation in the 12-week depression trial (Mao 2015). Community reports describe 200 to 600 mg per day, often split into two doses (anecdotal; the upper end exceeds the 400 mg per day EU label maximum).

Onset and duration: in open-label trials at 200 mg twice daily (400 mg per day), fatigue changed most after 1 week and kept declining to week 8 in 100 people with prolonged or chronic fatigue,⁽²⁴⁾ and stress symptoms improved after 3 days, with further gains at 1 and 4 weeks, in 101 adults with life-stress symptoms.⁽²⁵⁾ Planned on-and-off schedules for supplements like this are covered in how to cycle nootropics.

Timing considerations:

• Tested timing: split doses early in the day (200 mg before breakfast and 200 mg before lunch) in the anxiety trial, and 1 hour before the session in the exercise trials
• Users commonly take Rhodiola Rosea in the morning and early afternoon because some find it stimulating, and with or without food; reports differ, and no human trial compared times of day or food versus fasting

Extract standardization:

• Extracts with a different standardization deliver different amounts of rosavins and salidroside per milligram, so the trial doses do not transfer one-to-one

Animal-derived estimate: the lowest effective rat dose converts to at least about 12.5 times the 1,360 mg per day maximum of the human trials, an estimate and not a tested dose (see Neurogenesis in Rats).

Dosage forms:

• Capsules/tablets: Follow the manufacturer’s label dose
• Liquid extracts: 10-20 drops, 1-3 times daily (anecdotal, not studied)
• Tea: 1-2 teaspoons of dried root steeped in hot water for 5-10 minutes, 1-2 times daily (traditional preparation, not studied)

Rhodiola Rosea Side Effects & Safety

Rhodiola Rosea side effects are few. The EU herbal monograph lists headache, nausea, abdominal pain, diarrhoea, skin rash and itching, each with unknown frequency.⁽²⁾ In the 12-week trial in 57 adults with major depression, 6 of 20 Rhodiola Rosea users (30.0%) reported an adverse event, against 3 of 18 on placebo (16.7%) and 12 of 19 on sertraline (63.2%); the paper’s p = 0.012 compares all three groups and is not a test of any single pair. There were no treatment-related serious adverse events, nobody stopped Rhodiola Rosea or placebo early, and two people stopped sertraline because of adverse events.⁽³⁾

The 13.3 percentage-point gap between Rhodiola Rosea and placebo is not statistically significant (Fisher exact test, a significance test suited to small counts: p = 0.45). Against sertraline, the share reporting an adverse event was 33.2 percentage points lower on Rhodiola Rosea, about one extra person in every 3 on sertraline over 12 weeks (number needed to harm 3, the number of people treated for one extra person to be affected: 1 / 0.332 = 3.01, rounded down); the pair difference is not statistically significant (Fisher exact p = 0.056).

The other adverse events recorded on Rhodiola Rosea in that trial were dizziness in 2 of 20 users (0 of 18 on placebo) and nervousness in 2 of 20 (2 of 18 on placebo).⁽³⁾ Heart rate was lower, not higher, on Rhodiola Rosea during a cycling warm-up (136 versus 140 beats per minute, p = 0.001),⁽¹²⁾ and palpitations were recorded in 3 of 19 sertraline users and 0 of 20 Rhodiola Rosea users. Insomnia was recorded in 4 of 19 sertraline users and 0 of 20 Rhodiola Rosea users.⁽³⁾ Users commonly report dizziness and dry mouth or excess saliva; irritability, restlessness and trouble sleeping are reported mainly with late-day or high doses. Reports differ; these effects fit a mild stimulating action and were not measured in the human trials. Side effects shared across nootropic classes are covered in nootropics side effects.

Who should avoid Rhodiola Rosea:

• Children and adolescents under 18 (use not recommended in the EU monograph) and pregnant or breastfeeding women (safety not established; use not recommended)⁽²⁾
• People allergic to Rhodiola Rosea: hypersensitivity to the active substance is the one contraindication in the EU monograph⁽²⁾; allergy to related Crassulaceae plants is an inferred concern
• People with thyroid disease or severe liver or kidney disease: safety data for Rhodiola Rosea in these conditions are lacking, and no specific interaction is established; ask a clinician first
• Individuals with bipolar disorder: a case report describes mania in a 58-year-old man who used Rhodiola Rosea at about 3 times the recommended amount, and its authors state that safety in people vulnerable to bipolar disorder has not been established⁽²⁶⁾
• People with autoimmune conditions: inferred caution, because Rhodiola Rosea is described as immune-stimulating in traditional and supplement references; this is not tested in people with autoimmune disease
• Those with hormone-sensitive conditions such as breast cancer, uterine cancer or endometriosis: no safety data exist for Rhodiola Rosea in these conditions, and no hormonal effect of Rhodiola Rosea has been shown
• Individuals with low blood pressure: expected caution, because adaptogen herbs are reported to lower blood pressure in some users; the 12-week depression trial found no meaningful change in blood pressure or pulse on Rhodiola Rosea⁽³⁾

Potential drug interactions in detail:

Rhodiola Rosea slows the liver enzyme CYP2C9, which breaks down drugs such as warfarin and phenytoin. In 13 healthy volunteers, 14 days of a commercial Rhodiola rosea product lowered CYP2C9 activity, measured with losartan, by 21% (p = 0.023), with no significant effect on CYP1A2, CYP2C19, CYP2D6 or CYP3A4; the authors call the effect modest but possibly clinically relevant for CYP2C9 drugs with a narrow therapeutic range such as warfarin and phenytoin.⁽²⁷⁾ In vitro, extracts from six Rhodiola rosea clones inhibited CYP3A4 at concentrations of 1.7 to 3.1 micrograms per millilitre (the IC50, the concentration that halves enzyme activity) and the drug pump P-glycoprotein at 16.7 to 51.7 micrograms per millilitre.⁽²⁸⁾ The EU monograph lists no clinically relevant interactions,⁽²⁾ but the laboratory data (CYP2C9 in volunteers, CYP3A4 and P-glycoprotein in vitro) suggest an interaction is possible with warfarin, phenytoin and drugs cleared by CYP3A4 or P-glycoprotein, which is why those drug groups are listed as cautions.

• Antidepressants: a case report describes a 68-year-old woman with depression who developed vegetative syndrome, restlessness and trembling after adding Rhodiola Rosea to paroxetine, and its authors interpret the symptoms as a possible serotonergic syndrome⁽²⁹⁾; an excess of serotonin with SSRIs is also inferred from the MAO-A inhibition in vitro, and the combination has not been tested in people; avoid combining unless a pharmacist or doctor has reviewed it
• MAOIs: expected to add to MAO inhibition, inferred from the in vitro MAO-A and MAO-B inhibition; avoid the combination unless a clinician has reviewed it
• Blood pressure medications: interaction references list effects that may add up and lower blood pressure further (moderate caution); for losartan alone, the CYP2C9 test above lowered its conversion to the active form, which would weaken it. Both directions are inferred, not tested, and reports differ; the depression trial found no meaningful blood pressure change, so check blood pressure when combining
• Diabetes medicines: interaction references list a possible extra fall in blood sugar (moderate caution; inferred, not tested in the human trials); monitor blood sugar when combining
• Sedatives, antipsychotics, sleep medicines and alcohol: published case reports summarised in the EMA assessment report describe excessive sedation with diazepam (3 cases) and with haloperidol plus olanzapine (1 case), with the cause not established;⁽⁹⁾ alcohol is expected to add to sedation (inferred); avoid combining unless a pharmacist or doctor has reviewed it
• Immunosuppressants: interaction references list a possible weaker effect, because Rhodiola Rosea is described as immune-stimulating (inferred, not tested)
• Stimulants such as caffeine: may add to jitteriness or trouble sleeping, expected from a mild stimulating action and commonly reported by users; interaction references also list a possible rise in blood pressure, inferred from MAO inhibition (clinical relevance not determined), so avoid combining high doses and ask a pharmacist or doctor if you have high blood pressure

Long-term safety considerations:

• The longest human trial lasted 12 weeks, so long-term safety is not established
• None of the human trials in the evidence table tested dependence or withdrawal; in the De Bock 2004 exercise trial the single-dose benefit was still present after 4 weeks of daily use, so no tolerance was seen there; no dependence on Rhodiola Rosea is established, and reports differ among users on whether breaks from use are needed
• Tests on reproductive toxicity, genotoxicity and carcinogenicity are not available for Rhodiola Rosea preparations (EU monograph)⁽²⁾

When to consult a healthcare provider:

• If symptoms persist longer than 2 weeks of use (EU monograph advice)⁽²⁾
• Before combining with prescription medications, especially warfarin, phenytoin, antidepressants, blood pressure or diabetes medicines, or sedatives
• Before planned surgery: stopping herbal supplements about 2 weeks before is a common precaution, because of possible effects on blood pressure, bleeding-related drugs and anaesthesia (precaution, not based on Rhodiola trials)
• If you have any pre-existing health condition or take regular medication

Where to Buy Rhodiola Rosea

Rhodiola Rosea products differ in what they contain. About one in five of roughly 40 products sold as Rhodiola rosea contained no rosavin, and about 80% of the rest held less rosavin than registered herbal medicines and appeared to be mixed with other Rhodiola species.⁽¹³⁾

A label that states the rosavin and salidroside percentages and the mg dose is the one to choose; see Rosavin and Rhodiola Rosea Dosage for what those numbers mean.

aSquared Nutrition sells Rhodiola Rosea capsules (180 capsules, sold as a 90-day supply at 1,000 mg per serving).⁽³⁰⁾

Summary

Rhodiola Rosea is an adaptogenic root extract, usually standardized to 3% rosavins and 1% salidroside, whose best human evidence is reduced mental fatigue under stress in placebo-controlled trials, from single doses to 576 mg per day for 28 days.

With its adaptogenic qualities and its effects on stress, mental fatigue, reaction time and short-term endurance, Rhodiola Rosea fits people whose work or training pushes them into fatigue; memory and neurogenesis effects remain animal findings.

In the 57-person depression trial, neither Rhodiola Rosea nor sertraline differed significantly from placebo, and fewer Rhodiola Rosea users than sertraline users reported adverse events (not significant as a pair); Rhodiola Rosea also lowered CYP2C9 activity in a 14-day study of 13 volunteers, which may matter for people on warfarin or phenytoin.

Combining Rhodiola Rosea with prescription drugs calls for a healthcare professional’s review first.

FAQs

1. Olsson, Erik M et al. “A randomised, double-blind, placebo-controlled, parallel-group study of the standardised extract shr-5 of the roots of Rhodiola rosea in the treatment of subjects with stress-related fatigue.” Planta medica vol. 75,2 (2009): 105-12. doi:10.1055/s-0028-1088346↩↩
2. Committee on Herbal Medicinal Products. “European Union herbal monograph on Rhodiola rosea L., rhizoma et radix, Final, Revision 1 (EMA/HMPC/24177/2023).” European Medicines Agency, 20 Mar. 2024, https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-rhodiola-rosea-l-rhizoma-et-radix-revision-1%5Fen.pdf↩↩↩↩↩↩↩↩↩
3. Mao, Jun J et al. “Rhodiola rosea versus sertraline for major depressive disorder: A randomized placebo-controlled trial.” Phytomedicine vol. 22,3 (2015): 394-9. doi:10.1016/j.phymed.2015.01.010↩↩↩↩↩↩↩
4. Booker, A J, et al. “A metabolomic and phytochemical based study of Rhodiola species sourced from Asia and Europe.” Planta Medica vol. 81,16 (2015), doi:10.1055/s-0035-1565311↩
5. National Center for Biotechnology Information. “PubChem Compound Summary for CID 159278 (salidroside).” PubChem, https://pubchem.ncbi.nlm.nih.gov/rest/pug/compound/cid/159278/property/MolecularFormula,MolecularWeight/JSON↩
6. National Center for Biotechnology Information. “PubChem Compound Summary for CID 9823887 (rosavin).” PubChem, https://pubchem.ncbi.nlm.nih.gov/rest/pug/compound/cid/9823887/property/MolecularFormula,MolecularWeight/JSON↩
7. van Diermen, Daphne et al. “Monoamine oxidase inhibition by Rhodiola rosea L. roots.” Journal of ethnopharmacology vol. 122,2 (2009): 397-401. doi:10.1016/j.jep.2009.01.007↩
8. Zhang, Ying et al. “Pharmacokinetics, tissue distribution, and excretion of salidroside in rats.” Planta medica vol. 79,15 (2013): 1429-33. doi:10.1055/s-0033-1350807↩
9. Committee on Herbal Medicinal Products. “Assessment report on Rhodiola rosea L., rhizoma et radix, Final, Revision 1 (EMA/HMPC/24186/2023).” European Medicines Agency, 20 Mar. 2024, https://www.ema.europa.eu/en/documents/herbal-report/final-assessment-report-rhodiola-rosea-l-rhizoma-et-radix-revision-1%5Fen.pdf↩↩
10. Panossian, Alexander, et al. “Pharmacokinetics of Active Constituents of Rhodiola rosea SHR-5 Extract.” Comprehensive Bioactive Natural Products, Vol. 2: Efficacy, Safety and Clinical Evaluation I, edited by V. K. Gupta, Studium Press LLC, 2010, pp. 307-329.↩
11. Jówko, Ewa et al. “Effects of Rhodiola rosea supplementation on mental performance, physical capacity, and oxidative stress biomarkers in healthy men.” Journal of sport and health science vol. 7,4 (2018): 473-480. doi:10.1016/j.jshs.2016.05.005↩↩↩
12. Noreen, Eric E et al. “The effects of an acute dose of Rhodiola rosea on endurance exercise performance.” Journal of strength and conditioning research vol. 27,3 (2013): 839-47. doi:10.1519/JSC.0b013e31825d9799↩↩↩
13. Booker, Anthony et al. “The authenticity and quality of Rhodiola rosea products.” Phytomedicine vol. 23,7 (2016): 754-62. doi:10.1016/j.phymed.2015.10.006↩↩
14. Dimpfel, Wilfried et al. “Assessing the Quality and Potential Efficacy of Commercial Extracts of Rhodiola rosea L. by Analyzing the Salidroside and Rosavin Content and the Electrophysiological Activity in Hippocampal Long-Term Potentiation, a Synaptic Model of Memory.” Frontiers in pharmacology vol. 9 425. 24 May. 2018, doi:10.3389/fphar.2018.00425↩↩
15. Soluma. “Ingredients.” Soluma, https://mysoluma.com/pages/ingredients↩
16. Shevtsov, V A et al. “A randomized trial of two different doses of a SHR-5 Rhodiola rosea extract versus placebo and control of capacity for mental work.” Phytomedicine vol. 10,2-3 (2003): 95-105. doi:10.1078/094471103321659780↩
17. Darbinyan, V et al. “Rhodiola rosea in stress induced fatigue: a double blind cross-over study of a standardized extract SHR-5 with a repeated low-dose regimen on the mental performance of healthy physicians during night duty.” Phytomedicine vol. 7,5 (2000): 365-71. doi:10.1016/S0944-7113(00)80055-0↩
18. Vasileva, Liliya V et al. “Beneficial effect of commercial Rhodiola extract in rats with scopolamine-induced memory impairment on active avoidance.” Journal of ethnopharmacology vol. 193 (2016): 586-591. doi:10.1016/j.jep.2016.10.011↩
19. Cropley, Mark et al. “The Effects of Rhodiola rosea L. Extract on Anxiety, Stress, Cognition and Other Mood Symptoms.” Phytotherapy research : PTR vol. 29,12 (2015): 1934-9. doi:10.1002/ptr.5486↩
20. Darbinyan, V et al. “Clinical trial of Rhodiola rosea L. extract SHR-5 in the treatment of mild to moderate depression.” Nordic journal of psychiatry vol. 61,5 (2007): 343-8. doi:10.1080/08039480701643290↩
21. Chen, Q G et al. “The effects of Rhodiola rosea extract on 5-HT level, cell proliferation and quantity of neurons at cerebral hippocampus of depressive rats.” Phytomedicine vol. 16,9 (2009): 830-8. doi:10.1016/j.phymed.2009.03.011↩
22. Spasov, A A et al. “A double-blind, placebo-controlled pilot study of the stimulating and adaptogenic effect of Rhodiola rosea SHR-5 extract on the fatigue of students caused by stress during an examination period with a repeated low-dose regime.” Phytomedicine vol. 7,2 (2000): 85-9. doi:10.1016/S0944-7113(00)80078-1↩
23. De Bock, Katrien et al. “Acute Rhodiola rosea intake can improve endurance exercise performance.” International journal of sport nutrition and exercise metabolism vol. 14,3 (2004): 298-307. doi:10.1123/ijsnem.14.3.298↩
24. Lekomtseva, Yevgeniya et al. “Rhodiola rosea in Subjects with Prolonged or Chronic Fatigue Symptoms: Results of an Open-Label Clinical Trial.” Complementary medicine research vol. 24,1 (2017): 46-52. doi:10.1159/000457918↩
25. Edwards, D et al. “Therapeutic effects and safety of Rhodiola rosea extract WS® 1375 in subjects with life-stress symptoms–results of an open-label study.” Phytotherapy research : PTR vol. 26,8 (2012): 1220-5. doi:10.1002/ptr.3712↩
26. Whig, Rahat, and Raphael J. Leo. “Mania Associated With Rhodiola Rosea: An Adaptogen With Antidepressant Effects.” Prim Care Companion CNS Disord vol. 24,2 21cr02980. 17 Mar. 2022, doi:10.4088/PCC.21cr02980↩
27. Thu, Ole Kristian et al. “Effect of commercial Rhodiola rosea on CYP enzyme activity in humans.” European journal of clinical pharmacology vol. 72,3 (2016): 295-300. doi:10.1007/s00228-015-1988-7↩
28. Hellum, Bent H et al. “Potent in vitro inhibition of CYP3A4 and P-glycoprotein by Rhodiola rosea.” Planta medica vol. 76,4 (2010): 331-8. doi:10.1055/s-0029-1186153↩
29. Maniscalco, Ignazio, et al. “The interaction of Rhodiola rosea and antidepressants. A case report.” Neuropsychiatrie vol. 29,1 (2015): 36-8. doi:10.1007/s40211-014-0124-8↩
30. aSquared Nutrition. “Rhodiola Rosea.” aSquared Brands, https://asquarednutrition.com/products/rhodiola-rosea↩